|
Anti-STn Antibody
Description: Dysregulation of cellular glycosylation is a common characteristic of many cancers (1). The STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), also known as the sialyl-Tn antigen, is up-regulated in a wide variety of cancers (2). It is formed from the Tn antigen (GalNAcα1-O-Ser/Thr) through the action of the ST6GalNAc family of enzymes (3,4). STn-Keyhole Limpet Hemocyanin conjugate has been tested as an anti-cancer vaccine (5). The specificity of the anti-STn monoclonal antibody was shown by binding to bovine submaxillary mucin (BSM), which presents the STn antigen, and not to asialo-BSM (ref 2 and Figure 1 panel B). This antibody was previously marketed under HB-STn (3,4).
Preparation: Monoclonal antibodies were produced from the mouse hybridoma 3F1 clone (HB-STn). Purification: This IgG1 was purified by Protein G affinity chromatography. Catalog #: SBH-ASTn Formulation: Sterile filtered solution PBS, at a stock concentration of 640 ug/mL. Stability: Stable for 4 weeks at 4C. Stable for 6 months at -80C. Avoid repeated freeze-thaw cycles. Reconstitution: N/A Specificity Assay: To create asialo bovine submaxillary mucin (aBSM), 30mg of BSM (Sigma M3895) was treated treated with 5U of Neuraminidase (Sigma N2876) for 2 hrs at 37⁰C. Double dilution ELISAs were carried out by coating 96 well plates with a 1:2 serial dilution of 10ng/ml BSM or aBSM, blocking and incubating with a 1:4 serial dilution of 10ug/ml anti-STn (SBH-STn). After washing, plates were incubated with a goat-anti-mouse (IgG+IgM)-HRP conjugate (Thermo 31446) at 1:1000 dilution. After washing, plates were developed with 2x ABTS (Southern Biotech 0202-01). Net OD was measured at 405 – 650 nm. As low as 2ng/ml SBH-STn MAb could detect BSM coated at 25 ng/ml, with no detectable binding to aBSM (see Figure 1 panel (B) above). Usage: For research only. Not for use in diagnostic or therapeutic procedures. Country of Origin: USA We are open for suggestions and would be pleased to hear from you. |
|
